Foundayo vs. Wegovy

Are Foundayo and Wegovy the same kind of drug?

They're cousins: both are GLP-1 receptor agonists, but in different forms. Both mimic the gut hormone GLP-1 to curb appetite, and — unlike tirzepatide (Zepbound/Mounjaro) — both act on that single receptor rather than two [1], [2]. The difference is delivery: Foundayo is a small-molecule pill swallowed daily, while Wegovy is a peptide injected weekly.

Because they're so similar in mechanism, the weight-loss gap between them is smaller than between Foundayo and a dual-agonist injection [3], [4].

What is Foundayo?

Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist approved in 2026 for chronic weight management — the first GLP-1 pill approved for weight loss. It can be taken any time of day with no food or water restrictions, and titrates from 0.8 mg up to a maximum of 17.2 mg once daily [1].

In its pivotal ATTAIN-1 trial, the 17.2 mg dose produced a mean −11.1% of body weight at 72 weeks versus −2.1% on placebo, with about 55% of people losing at least 10% of their weight [1], [3].

What is Wegovy?

Wegovy (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved for chronic weight management and, since 2024, to reduce cardiovascular risk in adults with established heart disease and obesity or overweight (based on the SELECT trial) [2], [5]. It titrates from 0.25 mg up to a maintenance dose of 2.4 mg once weekly.

In its pivotal STEP 1 trial, Wegovy produced a mean −14.9% of body weight at 68 weeks, versus −2.4% on placebo [4].

How they work

Both mimic GLP-1, a gut hormone that reduces appetite, slows stomach emptying, and quiets "food noise" [1], [2].

The notable difference is chemistry: Wegovy is a peptide that has to be injected (it would be broken down in the gut), while Foundayo is a small molecule designed to survive digestion and work as a pill — which is why it took years longer to develop an oral GLP-1 that actually works for weight loss [1].

Effectiveness: how much weight loss?

Wegovy produced modestly more weight loss, but the two are in the same ballpark. There's no head-to-head trial, so the numbers come from separate studies. With that caveat: Wegovy averaged about −14.9% of body weight at 68 weeks, while Foundayo's top dose averaged about −11.1% at 72 weeks [3], [4].

For someone starting near 230 lb, that's roughly 34 lb on Wegovy versus about 25 lb on Foundayo — a real but not enormous difference, and much closer than Foundayo versus a dual-agonist injection like Zepbound. Individual response varies, and many people do well on either.

Beyond weight: heart protection

This is Wegovy's clearest advantage today. Semaglutide has an FDA-approved indication, backed by the large SELECT trial, to reduce the risk of major cardiovascular events (about a 20% reduction) in people with obesity and established heart disease [2], [5]. Foundayo does not yet carry a proven cardiovascular-outcomes benefit.

So for someone with obesity plus heart disease, Wegovy currently offers something Foundayo can't match — which can outweigh the convenience of a pill.

The trade-off: a pill vs. an injection

For people who would rather not inject, Foundayo changes the equation. It's a daily tablet with no food or water timing rules, which suits needle aversion, travel, or simple preference. Wegovy asks for a weekly subcutaneous injection but gives back a bit more weight loss and the proven heart benefit [1], [2].

Because the two are so close on weight loss, the form factor and the cardiovascular question often decide it.

What to expect: timeline

Both work gradually. Each starts low and steps up over months to limit nausea, and in both trials weight loss was still building at around 68–72 weeks before leveling off [3], [4]. Both are long-term treatments: stop either and appetite returns, so weight tends to come back.

They're meant to be taken and supervised over the long run alongside nutrition and activity changes [1], [2].

Dosing & administration

Foundayo: one tablet daily, any time — 0.8 mg up to 17.2 mg, increasing about every 30 days [1]. Wegovy: one injection weekly — 0.25 mg up to 2.4 mg, stepping up about every 4 weeks [2].

Side effects & safety

Because both act on GLP-1, the side effects are similar and mostly gastrointestinal — nausea, diarrhea, vomiting, constipation — usually mild to moderate and worst when starting or increasing the dose [1], [2].

Serious risks & who should not take these

Both carry a boxed warning for thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2]. Both can also cause pancreatitis, gallbladder disease, and low blood sugar when combined with insulin or a sulfonylurea [1], [2].

Because semaglutide clears slowly, Wegovy should be stopped at least 2 months before a planned pregnancy [2]. Tell your clinician your full history before starting either drug.

Cost & access

As an oral medication, Foundayo is positioned as a more accessible, lower-friction option — easier to ship, store, and take — with manufacturer self-pay and savings options. Wegovy runs in the four-figure range per month at list price, and weight-loss coverage is inconsistent across insurers for both.

Compounded semaglutide can be a lower-cost route, and the rules around it shifted as the shortage resolved [6]; quality and physician oversight vary by pharmacy, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy rather than an anonymous online seller.

A supervised program helps sort out coverage, savings, and which you can actually get.

Can you switch between them?

Yes, under medical supervision. People switch from the Wegovy injection to the Foundayo pill for convenience, or to Wegovy for a bit more weight loss or the heart benefit.

Because they're different molecules at different dose scales, a clinician restarts the appropriate dose ladder rather than matching milligrams, and you don't take two GLP-1 medications at once [1], [2].

Which is right for you?

• You want to avoid injections → Foundayo is an effective oral option that's close behind Wegovy on weight loss [1], [3].
• You have heart disease with obesity → Wegovy has the proven cardiovascular benefit (SELECT) [5].
• You want the most weight loss of these two → Wegovy edged Foundayo in trials, though the gap is modest [3], [4].

The right answer depends on your goals, your tolerance for injections, whether heart protection matters, and your insurance — exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both Foundayo and Wegovy, including dose titration and side-effect management.